Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DARIFENACIN

All products: Limited Use (codes 290)

Other products in the same Health Canada class (G04B, G04BD) — coverage varies; not interchangeable

  • Solifenacin (Vesicare): limited Use 290
  • Tolterodine l (Detrol LA): limited Use 290
  • Trospium chloride (Trosec): limited Use 290, Not a benefit
  • Sildenafil (Revatio): not a benefit

Enablex · DIN 02273217 · 7.5mg · extended release tablet

Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290 For patients with urinary frequency, urgency or urge incontinence who have: Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects. NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed. Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Enablex · DIN 02273217 Manufacturer: Searchlight Pharma Inc.; listing date 2011-12-15 Health Canada: Marketed since 2019-04-02 · brand ENABLEX · ATC G04BD10 DARIFENACIN · form Tablet (extended-release) · route Oral · ingredients DARIFENACIN (DARIFENACIN HYDROBROMIDE) 7.5 MG · company Searchlight pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.8058 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75871 · Verify on the e-Formulary ↗ (DIN 02273217)

Source record
DIN 02273217: Enablex Raw flags: sec12=Y, sec3=Y Item: 920000640; group id 908; item number 2174; lccId 00216; manufacturer id SLP Source form: ER Tab; strength: 7.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.6116; ministry $0.8058 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02273217 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75871
Interchangeable products
Apo-Darifenacin · DIN 02452510 · $0.8058 Jamp Darifenacin · DIN 02491869 · $0.8058
Shortage status: resolved shortage (ended 2024-06-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02273217
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

SOLIFENACIN SUCCINATE

· 30 products · Limited Use, codes 290 · strengths: 5mg, 10mg · Tab

TOLTERODINE L-TARTRATE

· 12 products · Limited Use, codes 290 · strengths: 2mg, 4mg, 1mg · SR Cap, Tab

TROSPIUM CHLORIDE

· 3 products · Listed, not a benefit (1), Limited Use, codes 290 (2) · strengths: 20mg · Tab

SILDENAFIL

· 46 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 20mg, 25mg, 50mg, 100mg · Tab

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: overactive bladder
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. MIRABEGRON · Limited Use, codes 290 INDICATIONS AND CLINICAL USE MYRBETRIQ (mirabegron) is indicated for the treatment of overactive bladder (OAB) with symptoms of urgency, urgency incontinence and urinary frequency. PM: https://pdf.hres.ca/dpd_pm/00035298.PDF; date June 02, 2016; DIN 02402874; fetched 2026-09-10 Product monograph PROPIVERINE HYDROCHLORIDE · Limited Use, codes 530 INDICATIONS AND CLINICAL USE Mictoryl/Mictoryl Pediatric (propiverine hydrochloride) is indicated for symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in patients with overactive bladder (OAB). PM: https://pdf.hres.ca/dpd_pm/00043480.PDF; date January 15, 2018; DIN 02460289; fetched 2026-09-10 Product monograph SOLIFENACIN SUCCINATE · Limited Use, codes 290 INDICATIONS AND CLINICAL USE VESICARE® (solifenacin succinate) is indicated for:  Treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urinary urgency and urinary frequency. PM: https://pdf.hres.ca/dpd_pm/00048963.PDF; date December 31, 2018; DIN 02277263; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE ENABLEX (darifenacin) is indicated for the treatment of overactive bladder. Overactive bladder is used to describe a collection of urinary symptoms composed of urgency, with or without urge incontinence, usually with frequency and nocturia, in the absence of proven infection or other obvious pathology. Geriatrics >65 Years Of Age In clinical studies (31.4% of patients were > 65 years of age), the safety and efficacy profile of darifenacin 7.5 mg and 15 mg in patients aged over 65 years are comparable to the younger population and were not affected by age. >75 Years Of Age In clinical studies, the safety and efficacy profile of darifenacin 7.5 mg and 15 mg in patients aged over 75 years are comparable to the younger population and were not affected by age. This information is based on 75 patients over 75 years of age, that were included in the four pivotal darifenacin phase III studies (See also PRECAUTIONS). Pediatrics The safety and effectiveness of ENABLEX in pediatric patients have not been established. https://pdf.hres.ca/dpd_pm/00049667.PDF PM date: not printed or not captured Source product: ENABLEX; DIN 02273217; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.